AACR: Nurix presents on lead BTK degrader for the treatment of B-cell malignancies

  Nurix Therapeutics Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced presentations covering its targeted protein degradation programs, including the structural disclosure of NX-2127 and new preclinical data for NX-2127 and NX-5948, highlighting their superior activity against acquired mutations in Bruton’s tyrosine kinase (BTK), a key therapeutic target in the treatment of B-cell malignancies. These data are being presented at the American Association for Cancer Research (AACR) Annual Meeting which is being held from April 14-19, 2023, in Orlando, FL.

https://www.biospace.com/article/releases/nurix-therapeutics-presents-data-at-the-american-association-for-cancer-research-aacr-annual-meeting-highlighting-activity-of-its-btk-targeted-protein-degraders-nx-2127-and-nx-5948-against-a-broad-range-of-btki-resistance-mutations/